Skip to main content
Erschienen in: Tumor Biology 10/2014

01.10.2014 | Research Article

Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a meta-analysis

verfasst von: Xiao-Bin Wang, Jie Li, Yi Han

Erschienen in: Tumor Biology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Observational studies on the prognostic role of preoperative serum carcinoembryonic antigen (CEA) in non-small cell lung cancer (NSCLC) are controversial. Electronic databases updated until June 1, 2014 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between preoperative serum CEA level and survival of patients with NSCLC. Survival data were aggregated and quantitatively analyzed. We performed a meta-analysis of 16 studies (n = 4,296 patients) that evaluated the correlation between preoperative serum CEA level and survival in patients with NSCLC. Combined hazard ratios suggested that preoperative serum CEA overexpression was associated with poor prognosis of overall survival (OS) (hazard ratio (HR) = 2.28, 95 % confidence interval (CI) 2.24–2.31) in patients with NSCLC. Meanwhile, for p-stage I NSCLC, the HR (95 % CI) was 1.98 (1.73–2.15). In the stratified analysis by patient source, significant risks were found among Asians and non-Asians. However, significant heterogeneity was observed among all studies. In the present meta-analysis, preoperative serum CEA overexpression indicates a poor prognosis for patients with NSCLC.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.CrossRefPubMed Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.CrossRefPubMed
2.
Zurück zum Zitat Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.PubMedCentralCrossRefPubMed Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Alberg A, Ford J, Samet J. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines. Chest. 2007;132:29–55S.CrossRef Alberg A, Ford J, Samet J. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines. Chest. 2007;132:29–55S.CrossRef
4.
Zurück zum Zitat Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol. 1995;13:1221–30.PubMed Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol. 1995;13:1221–30.PubMed
5.
Zurück zum Zitat Donnem T, Bremnes RM, Busund LT, Andersen S, Pezzella F. Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer. J Thorac Dis. 2012;4(2):212–3.PubMedCentralPubMed Donnem T, Bremnes RM, Busund LT, Andersen S, Pezzella F. Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer. J Thorac Dis. 2012;4(2):212–3.PubMedCentralPubMed
6.
Zurück zum Zitat Osarogiagbon RU. Predicting survival of patients with resectable non-small cell lung cancer: beyond TNM. J Thorac Dis. 2012;4(2):214–6.PubMedCentralPubMed Osarogiagbon RU. Predicting survival of patients with resectable non-small cell lung cancer: beyond TNM. J Thorac Dis. 2012;4(2):214–6.PubMedCentralPubMed
7.
Zurück zum Zitat Hanagiri T, Sugaya M, Takenaka M, Oka S, Baba T, Shigematsu Y, et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer. 2011;74(1):112–7.CrossRefPubMed Hanagiri T, Sugaya M, Takenaka M, Oka S, Baba T, Shigematsu Y, et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer. 2011;74(1):112–7.CrossRefPubMed
9.
Zurück zum Zitat Okada M, Nishio W, Sakamoto T. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1 000 consecutive resections for clinical stage I disease. Ann Thorac Surg. 2004;78(1):216–21.CrossRefPubMed Okada M, Nishio W, Sakamoto T. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1 000 consecutive resections for clinical stage I disease. Ann Thorac Surg. 2004;78(1):216–21.CrossRefPubMed
10.
Zurück zum Zitat Lee JH, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest. 2005;128:2298.CrossRefPubMed Lee JH, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest. 2005;128:2298.CrossRefPubMed
11.
Zurück zum Zitat N.I.H. Carcinoembryonic antigen: its role as a marker in the management of cancer. Br Med J. 1981;282:373.CrossRef N.I.H. Carcinoembryonic antigen: its role as a marker in the management of cancer. Br Med J. 1981;282:373.CrossRef
12.
Zurück zum Zitat American Thoracic Society and European respiratory Society. Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Med. 1997;156:320.CrossRef American Thoracic Society and European respiratory Society. Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Med. 1997;156:320.CrossRef
14.
Zurück zum Zitat Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.CrossRefPubMed Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.CrossRefPubMed
15.
Zurück zum Zitat Yusuf S, Peto R, Lewis J, et al. Blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–71.CrossRefPubMed Yusuf S, Peto R, Lewis J, et al. Blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–71.CrossRefPubMed
16.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMed DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMed
18.
Zurück zum Zitat Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMed Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMed
19.
Zurück zum Zitat Tomita M, Shimizu T, Ayabe T, Onitsuka T. Maximum SUV on positron emission tomography and serum CEA level as prognostic factors after curative resection for non-small cell lung cancer. Asia Pac J Clin Oncol. 2012;8(3):244–7.CrossRefPubMed Tomita M, Shimizu T, Ayabe T, Onitsuka T. Maximum SUV on positron emission tomography and serum CEA level as prognostic factors after curative resection for non-small cell lung cancer. Asia Pac J Clin Oncol. 2012;8(3):244–7.CrossRefPubMed
20.
Zurück zum Zitat Tomita M, Shimizu T, Ayabe T, et al. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. Anticancer Res. 2010;30(7):3099–102.PubMed Tomita M, Shimizu T, Ayabe T, et al. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. Anticancer Res. 2010;30(7):3099–102.PubMed
21.
Zurück zum Zitat Blankenburg F, Hatz R, Nagel D. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score. Tumour Biol. 2008;29(4):272–7.CrossRefPubMed Blankenburg F, Hatz R, Nagel D. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score. Tumour Biol. 2008;29(4):272–7.CrossRefPubMed
22.
Zurück zum Zitat Fukai R, Sakao Y, Sakuraba M. The prognostic value of carcinoem bryonic antigen in T1N1M0 and T2N1M0 non-small cell carcinoma of the lung. Eur J Cardiothorac Surg. 2007;32(3):440–4.CrossRefPubMed Fukai R, Sakao Y, Sakuraba M. The prognostic value of carcinoem bryonic antigen in T1N1M0 and T2N1M0 non-small cell carcinoma of the lung. Eur J Cardiothorac Surg. 2007;32(3):440–4.CrossRefPubMed
23.
Zurück zum Zitat Matsuoka K, Sumitomo S, Nakashima N. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 2007;32(3):435–9.CrossRefPubMed Matsuoka K, Sumitomo S, Nakashima N. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 2007;32(3):435–9.CrossRefPubMed
24.
Zurück zum Zitat Hsu WH, Huang CS, Hsu HS. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer. Ann Thorac Surg. 2007;83(2):419–24.CrossRefPubMed Hsu WH, Huang CS, Hsu HS. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer. Ann Thorac Surg. 2007;83(2):419–24.CrossRefPubMed
25.
Zurück zum Zitat Tsuchiya T, Akamine S, Muraoka M. Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer. 2007;56(3):341–8.CrossRefPubMed Tsuchiya T, Akamine S, Muraoka M. Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer. 2007;56(3):341–8.CrossRefPubMed
26.
Zurück zum Zitat Tomita M, Matsuzaki Y, Shimizu T. Relationship between serum carcinoembryonic antigen level and T status in non-small cell lung cancer. Anticancer Res. 2006;26(5B):3845–8.PubMed Tomita M, Matsuzaki Y, Shimizu T. Relationship between serum carcinoembryonic antigen level and T status in non-small cell lung cancer. Anticancer Res. 2006;26(5B):3845–8.PubMed
27.
Zurück zum Zitat Muley T, Dienemann H, Ebert W. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res. 2004;24(3b):1953–6.PubMed Muley T, Dienemann H, Ebert W. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res. 2004;24(3b):1953–6.PubMed
28.
Zurück zum Zitat Niizeki H, Morikawa T, Okushiba S. Survival and prognostic factors in resected cN2-pN0 non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2004;10(1):9–13.PubMed Niizeki H, Morikawa T, Okushiba S. Survival and prognostic factors in resected cN2-pN0 non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2004;10(1):9–13.PubMed
29.
Zurück zum Zitat Okada M, Sakamoto T, Nishio W. Characteristics and prognosis of patients after resection of nonsmall cell lung carcinoma measuring 2 cm or less in greatest dimension. Cancer. 2003;98(3):535–41.CrossRefPubMed Okada M, Sakamoto T, Nishio W. Characteristics and prognosis of patients after resection of nonsmall cell lung carcinoma measuring 2 cm or less in greatest dimension. Cancer. 2003;98(3):535–41.CrossRefPubMed
30.
Zurück zum Zitat Sawabata N, Ohta M, Takeda S. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg. 2002;74(1):174–9.CrossRefPubMed Sawabata N, Ohta M, Takeda S. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg. 2002;74(1):174–9.CrossRefPubMed
31.
Zurück zum Zitat Suzuki K, Nagai K, Yoshida J. The prognosis of surgically resected N2 non-small cell lung cancer: the importance of clinical N status. J Thorac Cardiovasc Surg. 1999;118(1):145–53.CrossRefPubMed Suzuki K, Nagai K, Yoshida J. The prognosis of surgically resected N2 non-small cell lung cancer: the importance of clinical N status. J Thorac Cardiovasc Surg. 1999;118(1):145–53.CrossRefPubMed
32.
Zurück zum Zitat Graziano SL, Tatum AH, Newman NB. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer. Cancer Res. 1994;54(11):2908–13.PubMed Graziano SL, Tatum AH, Newman NB. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer. Cancer Res. 1994;54(11):2908–13.PubMed
33.
Zurück zum Zitat Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001;18:705–19.CrossRefPubMed Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001;18:705–19.CrossRefPubMed
34.
Zurück zum Zitat Meert AP, Paesmans M, Martin B, et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2002;87:694–701.PubMedCentralCrossRefPubMed Meert AP, Paesmans M, Martin B, et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2002;87:694–701.PubMedCentralCrossRefPubMed
35.
Zurück zum Zitat Meert AP, Martin B, Paesmans M, et al. The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer. 2003;89:959–65.PubMedCentralCrossRefPubMed Meert AP, Martin B, Paesmans M, et al. The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer. 2003;89:959–65.PubMedCentralCrossRefPubMed
36.
Zurück zum Zitat Martin B, Paesmans M, Berghmans T, et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2003;89:55–64.PubMedCentralCrossRefPubMed Martin B, Paesmans M, Berghmans T, et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2003;89:55–64.PubMedCentralCrossRefPubMed
37.
Zurück zum Zitat Martin B, Paesmans M, Mascaux C, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. 2004;91:2018–25.PubMedCentralCrossRefPubMed Martin B, Paesmans M, Mascaux C, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. 2004;91:2018–25.PubMedCentralCrossRefPubMed
38.
Zurück zum Zitat Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005;92:131–9.PubMedCentralCrossRefPubMed Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005;92:131–9.PubMedCentralCrossRefPubMed
39.
Zurück zum Zitat Meert AP, Martin B, Delmotte P, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J. 2002;20:975–81.CrossRefPubMed Meert AP, Martin B, Delmotte P, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J. 2002;20:975–81.CrossRefPubMed
40.
Zurück zum Zitat Nakamura H, Kawasaki N, Taguchi M, et al. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax. 2006;61:140–5.PubMedCentralCrossRefPubMed Nakamura H, Kawasaki N, Taguchi M, et al. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax. 2006;61:140–5.PubMedCentralCrossRefPubMed
41.
Zurück zum Zitat Fan J, Wang L, Jiang GN, et al. The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. Lung Cancer. 2008;61:91–6.CrossRefPubMed Fan J, Wang L, Jiang GN, et al. The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. Lung Cancer. 2008;61:91–6.CrossRefPubMed
42.
Zurück zum Zitat Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. J R Stat Soc A. 1988;151:419–63.CrossRef Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. J R Stat Soc A. 1988;151:419–63.CrossRef
Metadaten
Titel
Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a meta-analysis
verfasst von
Xiao-Bin Wang
Jie Li
Yi Han
Publikationsdatum
01.10.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 10/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2301-6

Weitere Artikel der Ausgabe 10/2014

Tumor Biology 10/2014 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.